Background: This study was undertaken to determine if a clinically relevant drug-drug
therapy at home until therapeutic drug monitoring levels return within the therapeutic range and are deemed appropriate.
As a breakthrough to currently available therapies, the first CFTR modulating drug was approved on January 31, 2012. Ivacaftor (Kalydeco®, Vertex Pharmaceuticals Incorporated, Boston, MA) proved to be effective at treating the underlying cause of CF at the cellular level.
On July 2, 2015, a second CFTR modulator, lumacaftor/ivacaftor (Orkambi®, Vertex Pharmaceuticals Incorporated), was approved for CF patients age 12 years and older with two copies of F508del. This was later expanded to patients age 6 years and older on September 28, 2016.
In vitro data suggest that lumacaftor acts as a strong inducer of CYP3A4 enzymes. 4 These data also propose potential induction of CYP2B6, CYP2C8, CYP2C9, and CYP2C19 enzymes and inhibition of CYP2C8 and CYP2C9 enzymes. Several of these enzymes play a role in the metabolism of ibuprofen, suggesting that concomitant use of these medications could potentially alter plasma ibuprofen concentrations.
This interaction is also proposed in a recent article discussing therapeutic implications of drug-drug interactions in CF. 5 As mentioned in the prescribing information, data exist suggesting both induction and inhibition of enzymes; therefore, our study focused solely on the effect of lumacaftor/ivacaftor on the CYP450 substrate, ibuprofen. 4 However, to our knowledge, this is one of the first published case series reporting on clinical data of an interaction between ibuprofen and lumacaftor/ivacaftor.
The primary objective of this study was to determine if a clinically relevant drug-drug interaction occurred between ibuprofen and lumacaftor/ivacaftor. This was accomplished by comparing the highest ibuprofen plasma concentrations prior to and after initiation of lumacaftor/ivacaftor. A Wilcoxon signed rank sum test was used to compare the mean ibuprofen concentrations before and after starting lumacaftor/ ivacaftor. The analysis was conducted using SAS version 9.4 (SAS Institute, Inc., Cary, NC). P-values less than 0.05 were considered statistically significant.
| METHODS

| RESULTS
Ten patients met the inclusion criteria for this analysis; however, one patient was excluded due to use of rifampin prior to the ibuprofen therapeutic drug monitoring levels. The proportion of males and females was approximately equal (males = 56%) and the mean age of lumacaftor/ivacaftor initiation was 11.7 years (age range: 9-15 years).
There was no identifiable presence of liver or kidney disease in any of Liver function tests were not available for all patients; therefore, only five patients were included in this subset. b Serum creatinine levels were not available for all patients; therefore, only seven patients were included in the pre-lumacaftor/ivacaftor subset and six in the post-lumacaftor/ivacaftor subset.
the included patients. Additional demographic data can be found in Absolute doses ranged from 500 mg to 1400 mg twice daily, with a mean dose of 744 mg prior to initiation and 967 mg following initiation.
Ibuprofen plasma concentrations were drawn an average of 24 months prior to lumacaftor/ivacaftor initiation and repeated approximately 6 months following initiation.
Of the three ibuprofen concentrations obtained for each patient, the highest level was recorded as the peak concentration. The time at which this peak concentration occurred was noted to be the time at peak concentration. The average peak plasma concentration was 84.2 mcg/ mL (SD = 10.9) prior to lumacaftor/ivacaftor initiation and 47.9 mcg/mL (SD = 16.4) following initiation (P = 0.0039). Peak concentrations occurred at an average of 100 min (SD = 30) and 107 min (SD = 40)
prior to and following lumacaftor/ivacaftor initiation, respectively. Each patient included in the analysis showed a decrease in peak concentration following drug initiation, which is further illustrated in Table 2 and As noted, one patient was excluded from the analysis due to use of rifampin, another well-known CYP inducer, up until 2 weeks prior to ibuprofen therapeutic drug monitoring. This was the only instance that showed a lower ibuprofen peak plasma concentration within the pre- An additional three patients (not included in the analysis) had therapeutic drug monitoring levels drawn only after lumacaftor/ ivacaftor initiation. All three of these patients' peak concentrations were subtherapeutic, with the peak concentration averaging 41.7 mcg/mL. These patients received an average dose per weight of 22.6 mg/kg with an absolute dose range of 500-600 mg twice daily.
There are several limitations to this study. First, it was a retrospective chart review with a small sample size. Second, each patient was responsible for bringing in their own dose of ibuprofen to clinic; therefore, exact generic and actual bioavailability was variable and could have impacted pharmacokinetic parameters between the time periods. Additionally, timing of repeat ibuprofen pharmacokinetics in regards to lumacaftor/ivacaftor initiation was not consistent between patients and may have imposed an additional variable into the assessment. It is important to note that, while ibuprofen dosing regimens may have been further optimized at future visits, the intensive process of retesting levels at a subsequent visit was often declined by providers and/or patients due to the time involved. Lastly, blood samples were not routinely tested for all data collection points (i.e., liver and kidney function). However, absence of hepatic and renal dysfunction was confirmed through review of the electronic medical record.
In conclusion, our data suggest a clinically relevant drug-drug interaction exists between ibuprofen and lumacaftor/ivacaftor. This is clinically important as current literature and recommendations support the use of both medications in the pediatric CF patient. While there are no head-to-head trials comparing these therapies and their effect on lung function, our center feels that the long-term safety and efficacy as well as ease of administration and dosing favors the CFTR modulators.
With this new information, we have discontinued ibuprofen in several patients due to subtherapeutic ibuprofen concentrations and lack of desire to complete repeat testing. We propose using caution with concomitant use of ibuprofen and lumacaftor/ivacaftor following the analysis of these data as the current results demonstrate that lumacaftor induces the metabolism of ibuprofen, resulting in subtherapeutic concentrations. If concomitant use is desired, we recommend repeating ibuprofen pharmacokinetics following lumacaftor/ivacaftor initiation and adjusting the dose of ibuprofen, if necessary.
